DN-1508052

Part 1 (dose exploration in combination with toripalimab): Primary objective: To evaluate the safety and tolerability of subcutaneous injection of DN1508052-01 (DN052 for short) combined with toripalimab (JS001 for short) in the treatment of subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) of combined administration and/or the recommended combined dose (RP2D) of Phase II clinical trials. Secondary objectives: To further evaluate the safety and tolerability of combined treatment in subjects with advanced solid tumors; To evaluate the effectiveness of combined administration in subjects with advanced solid tumors; To evaluate the PK characteristics of combined administration; To evaluate the PD characteristics of combined administration; To evaluate the correlation between the biomarker PD-L1/HPV/EBV infection status of combined administration and the efficacy. Part 2 (cohort expansion in combination with toripalimab): Primary objective: To evaluate the preliminary efficacy of combined administration in subjects with advanced solid tumors whose disease has progressed after standard treatment or who are intolerant to standard treatment or have no standard treatment. Secondary objectives: To evaluate other efficacy indicators of the combination therapy in subjects with advanced solid tumors whose disease has progressed after standard treatment or who are intolerant to standard treatment or who have no standard treatment; To evaluate the safety and tolerability of the combination therapy in subjects with advanced solid tumors whose disease has progressed after standard treatment or who are intolerant to standard treatment or who have no standard treatment; To evaluate the PK characteristics of the combination therapy; To evaluate the PD characteristics of the combination therapy; To evaluate the correlation between the biomarker PD-L1/HPV/EBV infection status of the combination therapy and the efficacy